Lilly To Pay Up To $755M For Autoimmune Treatments

Law360, New York (December 22, 2009, 4:15 PM EST) -- Eli Lilly & Co. has agreed to purchase the rights to anti-inflammatory and autoimmune treatments from Incyte Corp. for up to $755 million, the companies have announced.

Lilly will make an initial payment of $90 million, and pay Incyte up to $665 million in possible future milestones, in addition to future royalties and sales payments if the products are successfully commercialized, according to a joint statement issued Monday.

The Indianapolis-based pharmaceutical giant will receive worldwide rights to develop and commercialize Incyte's oral therapies being developed for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.